Big Pharma Keeps CNS Pipeline In-House; GI/Metabolism Left To Specialists
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
For the analysis, published in the September/October 2010 Tufts CSDD Impact Report, researchers tracked clinical activity at the 50 largest pharmaceutical and biopharmaceutical companies ranked by total 2006 worldwide sales. The study analyzed factors related to clinical approval success for compounds entering the clinic between 1993 and 2004.